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Objectives: To examine the cost-effectiveness of primary debulking surgery (PDS) 
when compared to neoadjuvant chemotherapy (NACT) in the management of epithelial 
ovarian cancer (EOC) using Surveillance, Epidemiology, and End Results data linked to Medi-
care claims (SEER-Medicare).
Methods: Using a Markov model, the cost-effectiveness of PDS was compared to that of 
NACT. We modeled cost and survival inputs using data from women in the SEER-Medicare 
database with ovarian cancer treated by either PDS or NACT between 1992 and 2009. Direct 
and indirect costs were discounted by an annual rate of 3%. Utility weights were obtained from 
published data. The incremental cost-effectiveness ratio (ICER) of PDS compared to NACT 
was calculated.
Results: In our model, women with stage IIIC EOC had a higher mean adjusted treatment 
cost for PDS when compared to NACT ($31,945 vs $30,016) but yielded greater quality-
adjusted life-years (QALYs) (1.79 vs 1.69). The ICER was $19,359/QALY gained. Women 
with stage IV EOC had a higher mean adjusted treatment cost following PDS when compared 
to NACT ($31,869 vs $27,338) but yielded greater QALYs (1.69 vs 1.66). The ICER was 
$130,083/QALY gained. A sensitivity analysis showed that for both PDS and NACT the ICER 
was sensitive to incremental changes in the utility weight.
Conclusion: PDS is significantly more cost-effective for women with stage IIIC when compared 
to NACT. In women with stage IV EOC, PDS is also more cost-effective though the QALYs 
gained are much more costly and exceed a $50,000 willingness to pay.
Keywords: Markov model, gynecologic cancer, chemotherapy, up front surgery
Introduction
In 2016, it is estimated that more than 22,000 women will be diagnosed with ovarian 
cancer.  Of these, over 14,000 are expected to die from it. In women aged 40–59 and 
60–79 years, ovarian cancer is the fourth and fifth leading cause of cancer-related 
death, respectively, and is the leading cause of death from a gynecologic malignancy 
for all women in the USA. Over the past 40 years, the 5-year relative survival rate has 
only slightly increased.1
Ovarian cancer is associated with poor survival because it is usually diagnosed at 
an advanced stage. Because most women present with disease that extends beyond 
the pelvis, the 5-year survival rates remain less than 50%. Ovarian cancer survival is 
associated with a number of addressable factors, including: 1) timing to initiation of 
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chemotherapy following cytoreductive surgery;2 2) adminis-
tration of doublet chemotherapy with a platinum-based agent 
and a taxane;3 and 3) reduction of tumor burden by surgical 
debulking to no grossly visible residual disease.4
According to National Comprehensive Cancer Network 
(NCCN) guidelines, the primary treatment for ovarian cancer 
is primary debulking surgery (PDS), followed by platinum-
based chemotherapy. However, in certain circumstances, 
women are treated with chemotherapy first followed by 
surgery. A clinician’s decision to administer chemotherapy, 
also referred to as neoadjuvant chemotherapy (NACT), prior 
to cytoreductive surgery has also been evaluated as a factor 
associated with survival.3 
Several retrospective analyses have supported a survival 
advantage associated with PDS.5–7 Conversely, two prospec-
tive trials, the Chemotherapy or Upfront Surgery (CHORUS) 
trial and the European Organisation for Research and 
Treatment of Cancer (EORTC) trial, showed an equivalent 
survival but increased morbidity with PDS when compared 
to NACT.7–9 In a more recent retrospective analysis of Surveil-
lance, Epidemiology, and End Results data linked to Medicare 
claims (SEER-Medicare) data, Wright et al found that both 
treatments conveyed an equivalent survival advantage with 
a decrease in morbidity associated with NACT.10
The costs associated with caring for women with advanced 
ovarian cancer include those incurred during the initial treat-
ment, treatment of recurrences, and end-of-life care. To date, 
prior studies have not evaluated the cost-effectiveness of 
PDS compared to NACT. A cost-effectiveness analysis may 
provide additional insights into the overall benefit of each 
treatment strategy by comparing costs relative to survival. 
In a cost-effectiveness analysis, factors such as quality of 
life, cost per quality-adjusted life-year (QALY) gained, and 
survival can be integrated to provide a more complete inter-
pretation. The purpose of this investigation is to evaluate 
the cost-effectiveness of PDS when compared to NACT in 
women with advanced epithelial ovarian cancer (EOC) using 
survival and cost assumptions from SEER-Medicare data.
Methods
The study design was a retrospective population-based 
study using the SEER-Medicare database. University of 
California, Irvine Institutional Review Board approval was 
obtained (HS#2012-9076). Patient consent was not deemed 
necessary by the IRB. The SEER Database of the National 
Cancer Institute (NCI) contains approximately 97% of all 
incident cancer cases from tumor registries that covered 
14% of the US population in 1995 to 28% currently.11–13 
The SEER Program registries collect data on patient demo-
graphics, primary tumor site, tumor morphology and stage, 
first course of treatment, and follow-up for vital status. 
Among patients older than 65 years in SEER data, 93% 
were identified in the Medicare enrolment file and their 
records were successfully matched to SEER cases in 
the linkage process performed by the NCI and the 
Centers for Medicare and Medicaid Services.11,12 The 
Medicare claims database includes all inpatient hospital-
izations, outpatient visits, physician/supplier data, durable 
medical equipment, and hospice and home health care. 
All claims are longitudinal from the time of a person’s 
Medicare eligibility until death. Our analysis data include 
SEER cases from 1992 to 2009 and their Medicare claims 
from 1991 to 2010.
study population
A total of 38,792 patients diagnosed between January 1, 
1992 and December 31, 2009 with invasive ovarian cancer 
(SEER primary site code C569) as their only tumor or first 
primary tumor with the second tumor at least 2 years after 
the first ovarian cancer were identified in SEER data. We 
sequentially removed 287 cases with missing tumor histol-
ogy information, 117 with germ cell or sex cord tumor, 820 
with autopsy or death certificate only, 10,468 with age at 
diagnosis less than 66 years, 3,337 with missing tumor stage 
information, 8,731 with early stage (stage IIIB and below), 
36 with missing diagnosis month, and 4,696 without continu-
ous enrolment of Medicare Part A and Part B or who were 
ever enrolled in a health maintenance organization from the 
12th month prior to diagnosis. Using the International Clas-
sification of Disease, Ninth Revision, Clinical Modification 
(ICD-9-CM) procedure and diagnosis codes in claims data 
(Table S1), 4,714 patients who had received both ovarian 
cancer surgery and chemotherapy treatments were identified. 
In order to account for survival bias and capture true treat-
ment costs, patients observed for less than 5 months after 
cancer diagnosis were excluded, which resulted in exclud-
ing 196 patients, and the final study population consisted 
of 4,518 patients.
The surgery date was estimated by the admission date of 
inpatient stay for surgery. The starting date of chemotherapy was 
estimated by the date of first chemotherapy claim after cancer 
diagnosis. Patients who had an earlier surgery date or the same 
surgery and chemotherapy dates were placed in the PDS group 
and patients with earlier chemotherapy start dates were placed 
in the NACT group. Patients who started chemotherapy during 
the hospital stay for the surgery were identified as PDS.
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survival
Patients’ survival time was defined as the time between patho-
logic diagnosis and death or last follow-up. Survival estimates 
were based on final analysis data of 4,518 patients who 
were identified as having either PDS or NACT (Table 1). 
The Kaplan–Meier method and log-rank tests were used to 
estimate survival probability. Year 1–5 survival rates were 
calculated, and the Kaplan–Meier survival curves are given 
in Figure 1. The time horizon of 60 months was selected to 
correlate with 5-year survival data.
Costs
Costs in US dollars for patients treated by PDS or NACT with 
stages IIIC and IV ovarian cancer are shown in Tables 2 and 3. 
The costs were discounted by 3%. A 7-month time horizon 
was selected to represent costs associated with the initial 
treatment by PDS or NACT and to exclude downstream costs 
related to second-line treatment, palliation, or end-of-life 
care. The total cost of treatment was calculated as a summa-
tion of the costs incurred during the 7 months following initial 
diagnosis: 1) hospital inpatient costs; 2) physician costs; 
3) outpatient costs; 4) hospice costs; 5) home health costs; 
and 6) durable medical equipment costs. Costs associated 
with the treatment of recurrence and end-of-life care were 
assumed to be equivalent for PDS and NACT. Costs were 
inflation adjusted and presented in 2010 US dollars using 
the consumer price index for medical care services from the 
United States Bureau of Labor Statistics.14
Quality of life
Quality of life estimates were adjusted using standard util-
ity weights. Estimates assume that 1 year of perfect health 
is assigned a utility weight of 1 and that 1 year of imperfect 
health is assigned a utility weight of less than 1. In a theoreti-
cal patient with perfect health over a 5-year survival period, 
their survival QALY would equal 5. Conversely, if the same 
patient had a survival of 5 years but these were spent in a 
state of imperfect health with a utility weight of 0.5, then 
they would have a QALY equal to 2.5. In this analysis, utility 
weights were taken from published studies.15–17 The utility 
weight for chemotherapy was 0.77 for the first 1–5 months 
and 0.84 for months 6–12. An average (0.81) was taken to 
represent the 12-month period following diagnosis. A util-
ity weight of 0.94 was used to represent living with ovarian 
Table 1 Model estimates: clinical assumptions
Clinical parameter Model estimate Reference
Survival assumptions
stage iiiC survival ovarian cancer
 1-year survival treated with PDs 90.7% national Cancer institute26
 2-year survival treated with PDs 70.5% national Cancer institute26
 3-year survival treated with PDs 54.3% national Cancer institute26
 4-year survival treated with PDs 41.2% national Cancer institute26
 5-year survival treated with PDs 33.4% national Cancer institute26
 1-year survival treated with naCT 89.7% national Cancer institute26
 2-year survival treated with naCT 65.6% national Cancer institute26
 3-year survival treated with naCT 41.8% national Cancer institute26
 4-year survival treated with naCT 32.3% national Cancer institute26
 5-year survival treated with naCT 24.1% national Cancer institute26
stage iV survival ovarian cancer
 1-year survival treated with PDs 87.2% national Cancer institute26
 2-year survival treated with PDs 62.1% national Cancer institute26
 3-year survival treated with PDs 45.2% national Cancer institute26
 4-year survival treated with PDs 33.2% national Cancer institute26
 5-year survival treated with PDs 24.7% national Cancer institute26
 1-year survival treated with naCT 88.8% national Cancer institute26
 2-year survival treated with naCT 60.2% national Cancer institute26
 3-year survival treated with naCT 40.6% national Cancer institute26
 4-year survival treated with naCT 25.4% national Cancer institute26
 5-year survival treated with naCT 17.7% national Cancer institute26
Utility weights
Months 1–5 following chemotherapy 0.77 Chi et al5
Months 6–12 following chemotherapy 0.88 Chi et al5
Year 2 living with ovarian cancer 0.94 Chi et al5
Years 3–5 living with ovarian cancer 0.5 Chi et al5
Abbreviations: naCT, neoadjuvant chemotherapy; PDs, primary debulking surgery.
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cancer during the second year following diagnosis. A utility 
weight of 0.5 was used to represent the impact of cancer 
progression during years 3 through 5.
analysis
The economic analysis was performed using TreeAge Pro 
Software® (TreeAge Software Inc., Williamstown, MA, 
USA).18 A decision tree with a Markov state transition 
model was constructed to compare the cost-effectiveness of 
NACT and PDS in stage IIIC and IV EOC (Figures 1 and 2), 
respectively. Transition state probabilities and cost estimates 
were obtained using the SEER-Medicare database. The time 
horizon was 5 years. Effectiveness was measured in QALYs. 
The model classified subjects into two health states: alive 
with ovarian cancer and dead. Because there is a time value 
of money, direct and indirect costs associated with each 
intervention were discounted by an annual rate of 3% to 
determine their present value. The utility weights were taken 
from published data.19
The model assumptions include: 1) the major treatment-
related costs of PDS and NACT occur during the first 7 months 
of treatment; 2) quality-of-life utility weights change with 
disease progression; and 3) there are no significant dif-
ferences in the quality of life between PDS and NACT. 
A sensitivity analysis was performed to evaluate how numerical 
uncertainty can be apportioned to NACT and PDS.
Results
Base case
Survival and cost estimates were obtained from SEER-
Medicare data for patients treated with PDS and NACT. Of 
the 4,518 women deemed eligible for this analysis, 82.4% 
underwent PDS and 17.6% received NACT. Of women with 
stage IIIC and IV EOC, 85.4% and 78.5% received PDS, 
respectively. Survival data for years 1 through 5 were used at 
Markov transition state nodes. NACT was associated with a 
decreased 5-year overall survival for stage IIIC and IV EOC 
when compared to PDS. The hazard ratios were 1.36 and 
1.28 for stage IIIC and IV EOC, respectively. The 7-month 
treatment costs for stage IIIC patients treated with NACT or 
PDS were $59,769 and $59,805, respectively (Table 2). For 
women with stage IV EOC, the treatment costs were $60,442 
and $63,067 for NACT and PDS, respectively.
stage iiiC EOC
The cost of NACT when compared to PDS for women with 
stage IIIC EOC, using the model, is shown in Table 4. The 
cost of NACT was $30,016 compared to $31,945 for PDS. 
The incremental cost was $1,929 (Table 4). The effective-
ness for NACT was lower than that of PDS (1.69 and 1.79, 
respectively). The incremental cost-effectiveness ratio 
(ICER) was $19,359. A sensitivity analysis revealed the 
ICER was sensitive to the utility weight associated with 
NACT (Figure 2).
stage iV EOC
The results of the Markov model for women with stage IV 
EOC are given in Table 4. The analysis determined that the 
cost of NACT was $27,338 compared to $31,869 for PDS 
in women with stage IV EOC. The incremental cost was 
$4,531.50. The effectiveness of NACT was lower than that of 
PDS (1.66 and 1.69, respectively). The ICER was $130,083. 
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A sensitivity analysis revealed the ICER was sensitive to the 
utility weight associated with PDS (Figure 3).
Discussion
Many studies have reviewed the cost-effectiveness of inter-
ventions related to ovarian cancer.15–17,20–24 In a recent review 
article, several critical topics were discussed.24 Of these, much 
of the emphasis was directed toward driving treatment deci-
sions after the initial decision to treat with NACT or perform 
PDS. What is unfortunate is that, to date, no studies have 
looked at the cost-effectiveness of the very first decision that 
is made for patients with ovarian cancer, which is whether 
to treat with NACT or perform PDS. Moreover, this deci-
sion is possibly linked to the overall cost associated with the 
subsequent downstream decisions and outcomes.
The treatment of advanced ovarian cancer by PDS or 
NACT has been the subject of debate. Based on the SEER-
Medicare data used for the assumptions of this analysis, PDS 
Table 3 Model estimates: costs (2010 Us$)
Clinical parameter Mean SD
stage iiiC ovarian cancer with PDs
 7-month cost – hospital inpatient $40,511 $37,365
 7-month cost – physician claims $20,473 $14,528
 7-month cost – outpatient $5,833 $9,483
 7-month cost – hospice claims $74 $985
 7-month cost – home health $1,492 $2,889
 7-month cost – durable medical equipment $427 $2,597
 7-month total cost $68,811 $41,383
stage iiiC ovarian cancer with naCT
 7-month cost – hospital inpatient $36,911 $26,106
 7-month cost – physician claims $21,876 $14,176
 7-month cost – outpatient $6,994 $10,689
 7-month cost – hospice claims $21 $255
 7-month cost – home health $1,565 $2,649
 7 month cost – durable medical equipment $499 $2,310
 7-month total cost $67,867 $31,313
stage iV ovarian cancer with PDs
 7-month cost – hospital inpatient $44,621 $38,531
 7-month cost – physician claims $20,909 $14,428
 7-month cost – outpatient $4,212 $8,263
 7-month cost – hospice claims $124 $1,299
 7-month cost – home health $1,293 $2,709
 7-month cost – durable medical equipment $536 $3,099
 7-month total cost $71,695 $41,880
stage iV ovarian cancer with naCT
 7-month cost – hospital inpatient $35,336 $25,159
 7-month cost – physician claims $20,712 $14,771
 7-month cost – outpatient $6,919 $9,966
 7-month cost – hospice claims $90 $1,315
 7 month cost – home health $1,201 $2,388
 7-month cost – durable medical equipment $554 $2,525
 7-month total cost $64,813 $30,898
Abbreviations: naCT, neoadjuvant chemotherapy; PDs, primary debulking 
surgery; sD, standard deviation.
ClinicoEconomics and Outcomes Research 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
402
Forde et al
Table 4 Cost-effectiveness comparison of PDs treatment strategy versus naCT treatment strategy
Treatment strategy  
and cancer stage
Cost Incremental cost Effectiveness Incremental 
effectiveness
Incremental C/E
stage iiiC ovarian cancer
 naCT $30,016 1.69 QalYs
 PDs $31,945 $1,929 1.79 QalYs 0.1 QalYs $19,359
stage iV ovarian cancer
 naCT $27,338 1.66 QalYs
 PDs $31,869 $4,531 1.69 QalYs 0.03 QalYs $130,083
Note: Currency is 2010 Us$.
Abbreviations: C/E, cost-effectiveness ratio; naCT, neoadjuvant chemotherapy; PDs, primary debulking surgery; QalYs, quality-adjusted life-years.
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offers an increase in 5-year overall survival compared to 
NACT for both stage IIIC and IV ovarian cancer. In the past, 
survival comparisons between PDS and NACT have been 
criticized for a number of reasons, including: 1) physicians 
selecting sicker patients to NACT over PDS; 2) inability to 
accurately compare physician surgical proficiency in prior 
studies; 3) less than average optimal debulking rates; and 
4) changes in treatment paradigms over time.
There are several pivotal trials that have looked at sur-
vival and morbidity differences between PDS and NACT. 
In particular, the EORTC study was a prospective trial that 
randomized women with stage IIIC and IV ovarian can-
cer to either PDS or NACT.8 The analysis concluded that 
there was no statistically significant difference in mean or 
overall survival, but that PDS was associated with a higher 
complication rate. A second analysis, the CHORUS trial, 
randomized women with stage III and IV ovarian cancer 
to PDS or NACT.9 The results also showed no statistically 
significant difference in mean and overall survival between 
PDS and NACT. In addition, women undergoing NACT had 
a shorter hospital stay. For a number of reasons, both trials 
have sparked significant debate. First, the optimal debulking 
rates for the PDS arms are considerably low compared to 
what are considered standard optimal debulking rates. Also, 
there are concerns that patients who undergo NACT may 
be misclassified based on inaccurate pathologic interpreta-
tion of the extent of disease because of histologic changes 
imparted by chemotherapy. Finally, from these studies, it 
is very difficult to determine the level of surgeon profi-
ciency. It is worth mentioning that a recent retrospective 
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trial supports these conclusions and also found PDS to be 
associated with increased morbidity without evidence of a 
survival benefit.10
Conversely, Chi et al performed a retrospective study 
within a single institution.7 The study matched the time 
interval of the EORTC study with patients who underwent 
NACT and PDS at their institution for stage IIIC and IV ovar-
ian cancer. The authors found an increase in overall survival 
in the PDS arm compared to the EORTC trial and proposed 
that the survival difference may be attributed to extent of 
disease burden, expertise of the surgeon, and patient selec-
tion to NACT or PDS. As well, this study has fallen under 
scrutiny for a number of reasons, too. In particular, concerns 
are related to the validity of retrospective analysis and that 
physician bias cannot be measured retrospectively. In a recent 
retrospective analysis of 326 women with stage IIIC and 
IV ovarian cancer, NACT was associated with an increased 
optimal debulking rate but inferior 7-year survival. Overall, 
they found that the 7-year overall survival for women who 
were optimally debulked was significantly higher in women 
who underwent PDS.25
Given these disparities, we felt it important to provide 
additional clarity to the subtle differences between PDS 
and NACT with respect to survival and cost. In particular, 
a comparison of the cost relative to effectiveness with the 
inclusion of quality-of-life differences was performed. In 
this investigation, the base case assumes a slightly improved 
survival for PDS over NACT in both stage IIIC and 
stage IV ovarian cancer with hazard ratios of 1.36 and 1.28, 
respectively. NACT was slightly less costly than PDS for 
stage IIIC and significantly less costly for stage IV ovarian 
cancer. Based on this analysis, PDS is more cost-effective 
than NACT for the treatment of stage IIIC ovarian cancer and 
not as cost-effective as NACT for the treatment of stage IV 
ovarian cancer.
The strength of this analysis is that it includes assump-
tions based on a large number of women with stages IIIC 
and IV ovarian cancer and that the cost estimates are based 
on Medicare claims data linked to the SEER registry. Some 
of the limitations to using SEER-Medicare data are that the 
dataset only includes patients over 65 years, that there are 
more comorbidities in this population, and that generaliz-
ability to a broader population may be difficult. Additional 
limitations include inability to account for the extent of 
disease, the extent of surgery, and the amount of residual 
disease and inability to control for subtle unmeasured factors 
that may influence the decision for one treatment paradigm 
over the other. In addition, this study is limited by the biases 
that exist when using retrospective data such as selection 
bias and misclassification bias. Also, the same utility weight 
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was used for PDS and NACT during the first year following 
diagnosis, which may not accurately reflect the comparative 
morbidity between PDS and NACT within the first year of 
diagnosis. A sensitivity analysis showed that, if we consider 
PDS to be more morbid than NACT during the first year, 
PDS is still more cost-effective in stage IIIC ovarian cancer. 
What is unclear is to what extent PDS is more morbid and 
what the correct utility weights for each treatment should 
be to accurately reflect their relative impacts on quality of 
life. In addition, we assumed that the cost of end-of-life care 
would be similar for both treatment arms and therefore did 
not include end-of-life costs.
Conclusion
Our analysis found that PDS for advanced ovarian cancer 
is more cost-effective for stage IIIC disease. In stage IV 
ovarian cancer, the cost/QALY exceeds a willingness-to-pay 
threshold of $50,000/QALY; however, other factors used in 
medical decision-making should be considered as well. In the 
future, this may be offset by improvements in 5-year overall 
survival for women with advanced ovarian cancer that result 
from initiatives that: 1) centralize care of women with ovar-
ian cancer to high-volume providers and medical centers; 
2) improve compliance with NCCN guidelines; and 3) reduce 
barriers to access for disparate communities.
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Table S1 Procedure and diagnosis codes
Billing codes for ovarian cancer surgery
iCD-9 procedure codes (inpatient hospital claims data)
 54.4 Omentectomy, excision, destruction of peritoneal tissue
 65.2 Wedge resection or partial excision of ovary
 65.3* Unilateral oophorectomy
 65.4* Bilateral oophorectomy
 65.6* Bilateral salpingo-oophorectomy
 68.3* hysterectomy
 68.4* hysterectomy
 68.5* hysterectomy
 68.6* hysterectomy
 68.7* hysterectomy
 68.8 Pelvic exenteration
 68.9* hysterectomy
 70.32 Excision/destruction of cul de sac lesion
Billing codes for chemotherapy
DRg (inpatient hospital claims data)
 410
iCD-9 procedure code (inpatient, outpatient and physician/supplier 
claims data)
 99.25
iCD-9 diagnosis codes (inpatient, outpatient, and physician/supplier 
claims data)
 V58.1,V66.2,V67.2,E9331, E9307
hCPCs codes (outpatient and physician claims data)
  Q0083–Q0085, g0355–g0356, g0359–g0362, J8530, J8560, J8565, 
J8600, J8700, J8999, J9000–J9999, 964*, 965*
Revenue center codes (outpatient claims data)
 0331, 0332, 0335
Abbreviations: DRg, diagnosis related group; hCPCs, healthcare Common Procedure 
Coding System; ICD-9, International Classification of Diseases, Ninth Revision.
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